HK1080092A1 - Vegf antagonists for the treatment of diabetes - Google Patents

Vegf antagonists for the treatment of diabetes

Info

Publication number
HK1080092A1
HK1080092A1 HK06102834A HK06102834A HK1080092A1 HK 1080092 A1 HK1080092 A1 HK 1080092A1 HK 06102834 A HK06102834 A HK 06102834A HK 06102834 A HK06102834 A HK 06102834A HK 1080092 A1 HK1080092 A1 HK 1080092A1
Authority
HK
Hong Kong
Prior art keywords
vegf
diabetes
treatment
vegf antagonists
blocking
Prior art date
Application number
HK06102834A
Other languages
English (en)
Inventor
Mark W Sleeman
Stanley J Wiegand
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of HK1080092A1 publication Critical patent/HK1080092A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK06102834A 2003-03-28 2006-03-03 Vegf antagonists for the treatment of diabetes HK1080092A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45879003P 2003-03-28 2003-03-28
PCT/US2004/009246 WO2004087206A2 (en) 2003-03-28 2004-03-26 Methods of treating diabetes by blocking vegf-mediated activity

Publications (1)

Publication Number Publication Date
HK1080092A1 true HK1080092A1 (en) 2006-04-21

Family

ID=33131825

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06102834A HK1080092A1 (en) 2003-03-28 2006-03-03 Vegf antagonists for the treatment of diabetes

Country Status (17)

Country Link
US (1) US7052691B2 (xx)
EP (1) EP1608685B1 (xx)
JP (2) JP4730909B2 (xx)
AT (1) ATE354592T1 (xx)
AU (1) AU2004226417B2 (xx)
BR (1) BRPI0408749B1 (xx)
CA (1) CA2519787C (xx)
CY (1) CY1106530T1 (xx)
DE (1) DE602004004883T2 (xx)
DK (1) DK1608685T3 (xx)
ES (1) ES2278333T3 (xx)
HK (1) HK1080092A1 (xx)
MX (1) MXPA05008972A (xx)
PL (1) PL1608685T3 (xx)
PT (1) PT1608685E (xx)
SI (1) SI1608685T1 (xx)
WO (1) WO2004087206A2 (xx)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007001241A (es) 2004-07-30 2007-07-11 Regeneron Pharma Metodos para tratar diabetes tipo i mediante el bloqueo de la actividad mediada de vegf.
PT1861116E (pt) 2005-03-25 2015-11-04 Regeneron Pharma Formulações de antagonista do vegf
CN101478949A (zh) 2006-06-16 2009-07-08 瑞泽恩制药公司 适合玻璃体内施用的vegf拮抗剂的制剂
ES2345596B1 (es) * 2009-03-26 2011-07-13 Fundacion Progreso Y Salud Composicion para la prevencion o el tratamiento de la diabetes mellitus.
US20100330098A1 (en) * 2009-06-29 2010-12-30 Kuo Calvin J Methods to regulate glucose metabolism
KR20220097542A (ko) 2011-01-13 2022-07-07 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
AU2015208482B2 (en) 2014-01-25 2017-02-02 Chengdu Kanghong Biotechnologies Co., Ltd. Fusion protein inhibiting angiogenesis or growth and use thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3170005B1 (en) 2014-07-18 2019-04-10 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
IL290457B1 (en) 2015-12-30 2024-10-01 Kodiak Sciences Inc Antibodies and their conjugates
ITUB20169928A1 (it) * 2016-01-12 2017-07-12 Medical And Biotechnological Services In Sigla M B S Srl Formulazioni farmaceutiche per il trattamento del diabete
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021226444A2 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410533D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
CA2372053C (en) * 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
JP4723140B2 (ja) * 1999-06-08 2011-07-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改善された薬物動態特性を有する改変キメラポリペプチド
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases

Also Published As

Publication number Publication date
JP2006521397A (ja) 2006-09-21
EP1608685B1 (en) 2007-02-21
DE602004004883D1 (de) 2007-04-05
DE602004004883T2 (de) 2007-11-15
CA2519787C (en) 2012-06-05
CA2519787A1 (en) 2004-10-14
AU2004226417B2 (en) 2009-01-22
BRPI0408749A (pt) 2006-03-28
US20040213787A1 (en) 2004-10-28
CY1106530T1 (el) 2012-01-25
MXPA05008972A (es) 2005-11-04
PL1608685T3 (pl) 2007-07-31
ATE354592T1 (de) 2007-03-15
WO2004087206A2 (en) 2004-10-14
JP4730909B2 (ja) 2011-07-20
US7052691B2 (en) 2006-05-30
ES2278333T3 (es) 2007-08-01
EP1608685A2 (en) 2005-12-28
PT1608685E (pt) 2007-05-31
DK1608685T3 (da) 2007-06-11
SI1608685T1 (sl) 2007-08-31
WO2004087206A3 (en) 2004-12-16
BRPI0408749B1 (pt) 2016-10-04
AU2004226417A1 (en) 2004-10-14
JP2011037894A (ja) 2011-02-24

Similar Documents

Publication Publication Date Title
HK1080092A1 (en) Vegf antagonists for the treatment of diabetes
HK1105167A1 (en) Methods of treating type i diabetes by blocking vegf-mediated activity
ATE321048T1 (de) Beta-amino-tetrahydroimidazo(1,2-a)pyrazine und - tetrahydrotriazolo(4,3-a)pyrazine als dipeptidyl peptidase inhibitoren zur behandlung oder prevention von diabetes
AP1913A (en) Substituted benzazoles and use thereof as raf kinase inhibitors
MXPA05010819A (es) Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
WO2006023649A3 (en) Treatment of severe multiple sclerosis
MY169308A (en) Treatment of tnf? related disorders
EA200801118A1 (ru) Способ ингибирования flt3 киназы
WO2005107726A3 (en) Method for the treatment of back pain
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
TW200716673A (en) Use of TNF &ahr; inhibitor for treatment of erosive polyarthritis
WO2003105840A3 (en) SPHINGOSINE KINASE INHIBITORS
PT1682126E (pt) Benzazois substituídos e sua utilização como inibidores da quinase raf
WO2004084943A8 (en) Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
WO2007073497A3 (en) Calcium channel antagonists
WO2006060787A3 (en) Delaying or preventing onset of multiple sclerosis
WO2007075852A3 (en) Calcium channel antagonists
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
EA200800766A1 (ru) Ингибиторы pi3k для лечения эндометриоза
WO2003037310A3 (en) Use of inhibitors of the abc drug transporter to increase the activity of anti-microbial agents
WO2004009773A3 (en) Methods and compositions for activating or inhibiting vegf-d and vegf-c
WO2006016192A3 (en) Combination therapy with nk3 receptor antagonists for the treatment of schizophrenia
DE60214019D1 (de) Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren
ATE533769T1 (de) Als kinaseinhibitoren geeignete pyrrolotriazinverbindungen
TW200603792A (en) Monotherapy for the treatment of psoriasis with cyclooxygenase-2 selective inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190326